Quick Answer: An MFDS licence carries no legal weight at FDA. There is no mutual recognition agreement between Korea and the United States for medical device product decisions, and FDA grants clearance through a 510(k), not "approval." Korea's position is more internationally connected than most exporting countries — MFDS is one of twelve authorities on WHO's July 2026 transitional Listed Authority list, and an Affiliate Member of MDSAP — but neither status changes how FDA reviews a Korean manufacturer's submission, because both frameworks describe what other regulators may do with MFDS's decisions, not what FDA does with them. What genuinely transfers is evidence: an ISO 13485-certified quality system substantially aligns with FDA's Quality Management System Regulation (QMSR), effective since 2 February 2026, and KOLAS-accredited test data is credible internationally, though FDA acceptance still turns on the standard and version tested, not the accrediting body.

MFDS and FDA ask different questions — even though Korea is more internationally connected than most

The Ministry of Food and Drug Safety regulates medical devices under the Medical Devices Act, applying a four-tier, risk-based classification broadly aligned with GHTF/IMDRF principles. MFDS Notice 2026-6, issued this year, tightened those classification definitions further and introduced clearer IMDRF-aligned criteria for combination, integrated, and single-use devices. None of that determines your FDA classification. As with any foreign regulatory file, the reverse holds too: FDA clearance doesn't shorten or bypass MFDS review for a device you also want to sell in Korea. If you're weighing this same question against a European file, what actually transfers from a CE Mark to a 510(k) works through the identical logic — evidence transfers, status doesn't.

Korea's case is worth pausing on specifically, because on paper it looks more connected than most exporting countries. MFDS sits on WHO's list of transitional Listed Authorities for medical devices, published July 2026 — one of only twelve regulators named. It's a long-standing IMDRF member and an Affiliate Member of MDSAP. None of that gives a Korean manufacturer's FDA submission a shortcut, and it's worth being precise about why. WHO's tWLA framework describes regulators that other regulators may choose to rely on — it says nothing about FDA relying on MFDS. FDA is tWLA-listed too, and doesn't need to lean on another authority's assessment to clear a device for its own market. The listing is real and reflects genuine international standing; it just answers a different question than the one a Korean exporter is actually asking.

The MDSAP nuance worth getting right

This one is commonly blurred, so it's worth stating precisely. MDSAP has three participation tiers: full Members (Australia's TGA, Brazil's ANVISA, Health Canada, Japan's MHLW/PMDA, and the US FDA), Official Observers, and Affiliate Members. MFDS holds Affiliate Member status — a real form of participation, but a different and narrower one than the five full Members.

Here's why that distinction matters less than it sounds for a Korean manufacturer targeting the US. MDSAP audits the manufacturer, not the manufacturer's home regulator. Any manufacturer, regardless of where it's based, can engage a recognised MDSAP Auditing Organization for an audit that covers the requirements of the program's full Members. If FDA is included in the audit's scope, FDA — as a full Member — accepts that audit report as a substitute for routine surveillance inspections. That's true for a Korean manufacturer exactly as it would be for anyone else, and it has nothing to do with MFDS's own membership tier.

MFDS's Affiliate status describes something different: how MFDS itself uses MDSAP for its own domestic purposes. When a manufacturing site submits an MDSAP certificate and audit report during a KGMP audit, MFDS may grant an exemption from on-site inspection and conduct a document-based review instead. That's a genuine domestic benefit, worth knowing about, and entirely separate from what an MDSAP audit does for you at FDA.

What genuinely transfers: your quality system, with a telling domestic exception

The QMSR took effect on 2 February 2026 and incorporates ISO 13485:2016 by reference into 21 CFR Part 820. If your quality system is ISO 13485-certified, it now substantially aligns with what FDA expects — the same shift we've covered for ISO 13485 generally and under QMSR specifically. The same caution applies here as everywhere else: an ISO 13485 certificate is not accepted in lieu of an FDA inspection. An MDSAP audit report is.

Here's the useful, slightly ironic detail: Korea's own domestic requirement, KGMP, illustrates exactly why credentials don't transfer between regulators — and it does so in Korea's own backyard. Multiple current regulatory sources note that ISO 13485 certification does not replace KGMP compliance; MFDS applies its own Korea-specific procedural and inspection criteria on top of it, reinforced by a February 2026 update to the KGMP framework. Foreign manufacturers entering Korea are explicitly warned not to assume their ISO 13485 certificate is sufficient there. If that's true of ISO 13485 at MFDS, the reverse is equally true of KGMP at FDA: a KGMP certification, however rigorous, is a Korea-specific credential that FDA has no mechanism to recognise. The lesson generalises cleanly in both directions, and Korea happens to be the clearest illustration of it.

Testing: KOLAS accreditation is credible, not a formal FDA pathway

Korea's national lab accreditation body, KOLAS (Korea Laboratory Accreditation Scheme), accredits testing and calibration laboratories under ISO/IEC 17025 and has been a signatory to the ILAC Mutual Recognition Arrangement since 2000, with its accreditation scope extended specifically to medical testing in 2016. That's real, internationally recognised technical competence — the same structural credibility NABL carries for Indian labs, or any ILAC-signatory accreditation body carries anywhere.

What it isn't is a formal FDA recognition scheme. FDA doesn't maintain a list of accredited foreign lab bodies whose stamp guarantees acceptance of test data. What matters to FDA review is whether your testing followed the FDA-recognised version of the relevant standard — the ISO 10993 series for biocompatibility, IEC 60601 series for electrical safety — on your finished device, with complete, traceable documentation. A KOLAS-accredited lab is well-positioned to produce exactly that kind of data. The accreditation supports credibility; confirming that the specific tests, standard versions, and endpoints actually match what your predicate and product code require is a separate mapping exercise, and one worth doing deliberately — it's the kind of gap analysis Complizen's Superagent platform is built to run against your actual file rather than a general assumption about what "should" carry over.

Korea's own reform makes the predicate concept familiar — not transferable

This is genuinely useful context, and it cuts in a specific direction. MFDS operates its own domestic equivalence concept: a Class II device approved or certified three or more times against the same equivalent product can be publicly designated a "Recognized Substantially Equivalent" device — roughly 350 Class II product types currently qualify, mostly well-established categories like surgical gloves and drapes. A device matching one of these gets a simplified review, in some cases handled by an MFDS-accredited third-party reviewer with an official turnaround of around five days, provided the raw materials match exactly; otherwise a full technical review applies. If your device went through this route, or MFDS's broader equivalence-review process for referencing a previously approved device, you've already practiced the skill of building an equivalence argument.

The substance doesn't carry over, though. FDA's substantial equivalence comparator has to be a device already legally marketed in the United States — a 510(k)-cleared predicate — not an MFDS-recognized one, and Korea's designated-SE list has no relationship to FDA's predicate universe. Choosing the right predicate device is a US-specific exercise regardless of how comfortable you are with the equivalence concept elsewhere.

One signal worth taking seriously either way: if your device didn't qualify for Korea's equivalence pathway and required full clinical evidence as a novel submission at MFDS, treat that as an early flag to check the US predicate landscape too — the same absence of a comparator may recur, and if it does, De Novo rather than 510(k) becomes the relevant pathway.

Two different in-country roles, two different regulators

A specific, avoidable mix-up: Korea requires foreign manufacturers to designate a Korea License Holder (KLH) — a locally based responsible party for MFDS purposes. FDA separately requires a US Agent for any foreign manufacturer distributing in the United States. These are two roles serving two regulators; having a KLH in place for Korea does nothing for your FDA obligations, and vice versa. As with any foreign manufacturer, US Agent designation and establishment registration are conditions of commercial distribution in the US, not of 510(k) clearance — registering before you have a US buyer starts an annual fee clock for no benefit.

What it costs at FDA in FY2027

FDA fees don't vary by country of origin. In FY2027, running 1 October 2026 through 30 September 2027: a standard 510(k) is $28,653, or $7,163 with small business status; annual establishment registration is $13,785, with no small business reduction.

Korean manufacturers qualify for small business status the same way any foreign manufacturer does — through a National Taxing Authority Certification rather than a US tax return, bearing the official seal of the relevant national tax authority (Korea's National Tax Service) and confirming gross receipts in both local currency and US dollars. FDA requires this at least 60 days before the fee is due and states plainly it will not refund the difference if you pay standard and qualify later.

Two clocks, moving at different speeds for different reasons

MFDS's own reforms have been unusually active. A "Market Immediate Entry Medical Technology" fast-track, launched January 2026 for internationally-evaluated innovative devices, is reported to compress the gap between MFDS authorization and clinical use from as long as 490 days down to 80–140 days for qualifying devices. That's a genuine, recent acceleration on the Korean side — and it has no bearing on FDA's own timeline.

FDA's MDUFA V goal is a decision within 90 FDA days for 95% of 510(k) submissions. "FDA days" and calendar days aren't the same thing: the clock pauses whenever FDA is waiting on you, most commonly during an Additional Information request, so a 90-day goal can run well past that in real elapsed time. Whatever speed MFDS is now moving at domestically, budget FDA review as its own independent timeline — the two clocks don't influence each other in either direction.

Common mistakes

Assuming MFDS's international standing creates an FDA shortcut. WHO's tWLA listing and MDSAP Affiliate status both describe what other regulators may do with MFDS's decisions — not what FDA does with them.

Treating KGMP as interchangeable with ISO 13485, or vice versa. MFDS explicitly does not accept ISO 13485 in place of KGMP. The same non-transferability runs the other way at FDA.

Assuming an MFDS "substantially equivalent" comparison satisfies FDA's predicate requirement. The comparator has to be a US-cleared device. The skill transfers; the specific device doesn't.

Confusing a Korea License Holder with a US Agent. Two roles, two regulators, no substitution between them.

Registering a US establishment before there's a US buyer. It's a distribution requirement, not a submission requirement, and it starts an annual fee for no immediate benefit.

Frequently asked questions

Does an MFDS licence help with FDA clearance? Not as a credential — there's no mutual recognition agreement between MFDS and FDA for product decisions, and an MFDS licence has no legal standing there. It helps indirectly, through the evidence behind it: an ISO 13485-certified quality system aligns substantially with FDA's QMSR, and KOLAS-accredited testing carries real credibility, though FDA's acceptance still depends on the specific standard tested, not the accrediting body.

Is MFDS recognised by the FDA? Not in the sense of FDA relying on MFDS's decisions. MFDS is one of twelve authorities on WHO's July 2026 transitional Listed Authority list for medical devices, and an Affiliate Member of MDSAP — genuine international standing, but both describe what other regulators may do with MFDS's assessments, not what FDA does with them when reviewing a Korean manufacturer's own submission.

What's the difference between MDSAP Member and Affiliate Member status? MDSAP has five full Members — Australia, Brazil, Canada, Japan, and the US — whose regulators mutually accept MDSAP audits in place of their own routine inspections. MFDS holds the narrower Affiliate Member status, which mainly governs how MFDS itself uses MDSAP for its own domestic KGMP purposes. It doesn't affect whether FDA (a full Member) accepts an MDSAP audit for a Korean manufacturer — that depends on whether FDA was included in the audit's scope, not on MFDS's membership tier.

Does ISO 13485 satisfy Korea's KGMP requirement? No, and this is explicitly and repeatedly flagged as a common mistake by foreign manufacturers entering Korea. MFDS applies its own Korea-specific procedural and inspection criteria under KGMP, on top of ISO 13485 rather than instead of it. The same logic applies in reverse: a KGMP certification carries no weight at FDA.

Will FDA accept test data from a KOLAS-accredited Korean lab? It can, on the same basis as testing from any lab anywhere. KOLAS accreditation under ISO/IEC 17025, recognised through the ILAC Mutual Recognition Arrangement, is a genuine quality signal. FDA's acceptance depends on whether the specific test followed the FDA-recognised standard and version for your device type with complete documentation — not on which national body accredited the lab.

Can I use my MFDS equivalence review for my FDA submission? No. MFDS's own equivalence concepts — including its "Recognized Substantially Equivalent" designation for around 350 Class II product types — compare against devices registered or recognized within Korea. FDA requires comparison against a device already legally marketed in the United States. If your device needed full clinical evidence at MFDS because it didn't qualify for equivalence review, treat that as an early signal to check the US predicate landscape too.

Do I need a US Agent if I already have a Korea License Holder? Yes, separately. A KLH satisfies MFDS's requirement for a locally based responsible party in Korea. FDA requires its own US Agent for any foreign manufacturer distributing in the United States. Neither substitutes for the other.

What does FDA clearance cost for a Korean manufacturer? The same published fees as any manufacturer. In FY2027, a standard 510(k) is $28,653, or $7,163 with small business status, plus $13,785 for annual establishment registration. Korean manufacturers qualify for small business status through a National Taxing Authority Certification from Korea's National Tax Service rather than a US tax return.

Does MFDS's new fast-track pathway affect my FDA timeline? No. The "Market Immediate Entry Medical Technology" fast-track, launched January 2026, compresses MFDS's own approval-to-clinical-use timeline for qualifying devices. It has no bearing on FDA's MDUFA V review goals, which run as an entirely separate process on an entirely separate clock.

Is Korea's medical device regulatory system more internationally connected than other exporting countries? In several formal respects, yes — MFDS is IMDRF-active, tWLA-MD listed, and an MDSAP Affiliate Member, a stronger international profile than several other major manufacturing-hub regulators hold. None of that changes what FDA requires from a Korean manufacturer's own 510(k) submission, which is evaluated on its own evidence regardless of MFDS's standing elsewhere.

Key takeaways

International standing doesn't create an FDA shortcut. MFDS's WHO tWLA listing and MDSAP Affiliate status are genuine, but both describe what other regulators may do with MFDS's decisions — not what FDA does with a Korean manufacturer's submission.

QMSR is the real advantage, if you hold ISO 13485. Since February 2026, your quality system substantially aligns with FDA's expectations — though a certificate still isn't accepted in lieu of inspection the way an MDSAP report is.

KGMP proves the rule by being the exception nobody expects. MFDS doesn't accept ISO 13485 in place of KGMP domestically. That's the clearest available reminder that FDA won't accept KGMP either.

The equivalence skill transfers; the specific comparator doesn't. MFDS's own "Recognized Substantially Equivalent" designation is good practice for building this kind of argument — but your FDA comparator has to be a US-cleared device, not an MFDS-recognized one.

Two clocks, two regulators, no shared timeline. MFDS's recent fast-track reforms are real and unrelated to FDA's own MDUFA V review goals. Budget each independently.

Complizen helps international medical device manufacturers reach FDA 510(k) clearance, combining a software platform for in-house regulatory teams with full-service consultancy for teams without in-house FDA expertise.

Working out whether your existing quality and testing evidence actually maps to what FDA requires — rather than assuming it does because it satisfied MFDS — is the highest-leverage call to get right before you scope testing. Complizen's regulatory strategy engagement maps your device to a US pathway, product code, and predicate shortlist, reviewed by a senior FDA expert. See how the strategy service works →

References

  1. FDA — Quality Management System Regulation (QMSR). https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
  2. FDA — Medical Device Single Audit Program (MDSAP). https://www.fda.gov/medical-devices/cdrh-international-affairs/medical-device-single-audit-program-mdsap
  3. FDA — MDUFA Performance Goals and Procedures, Fiscal Years 2023 Through 2027. https://www.fda.gov/media/73507/download
  4. Federal Register — Medical Device User Fee Rates for Fiscal Year 2027. https://www.federalregister.gov/documents/2026/07/30/2026-15335/medical-device-user-fee-rates-for-fiscal-year-2027
  5. WHO — List of transitional WHO Listed Authorities for medical devices (tWLAs-MD), as of 1 July 2026 (PDF). https://cdn.who.int/media/docs/default-source/medicines/regulatory-systems/wla/list-of-transitional-wlas_md.pdf
  6. MDSAP — Benefits and Use (MDSAP.global, program-affiliated site). https://www.mdsap.global/about/benefits-and-use
  7. Emergo by UL — Primer on South Korea's Medical Device Regulatory System (secondary source; regulatory consultancy). https://www.emergobyul.com/news/primer-south-koreas-medical-device-regulatory-system
  8. RegDesk — MFDS Notice 2026-6: A Detailed Comparison of Old vs. New Medical Device Regulatory Requirements (secondary source; regulatory consultancy). https://www.regdesk.co/blog/mfds-notice-2026-6-a-detailed-comparison-of-old-vs-new-medical-device-regulatory-requirements/
  9. MFDS — Approval Process for Medical Devices (official ministry page, English). https://www.mfds.go.kr/eng/wpge/m_39/denofile.do
  10. Emergo by UL — Medical Device Classification in South Korea (secondary source; regulatory consultancy). https://www.emergobyul.com/services/south-korea-medical-device-classification
  11. ILAC — KOLAS, Korea, Signatory Status. https://ilac.org/latest_ilac_news/kolas-korea-signatory-status/
  12. KATS (Korean Agency for Technology and Standards) — KOLAS Accreditation Scheme overview. https://www.knab.go.kr/en/Introduction.do
  13. MedDeviceGuide — South Korea Digital Medical Products Act (DMPA): Complete Compliance Guide (secondary source). https://meddeviceguide.com/blog/south-korea-digital-medical-products-act-dmpa-guide
  14. KoreaBiomedical — Korea to fast-track innovative medical devices into hospitals in as little as 80 days (secondary source; trade press, reporting the 26 January 2026 MOHW/MFDS announcement). https://www.koreabiomed.com/news/articleView.html?idxno=30423